Timber Pharmaceuticals - TMBR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.00
  • Forecasted Upside: 3,348.28 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.45
▲ +0.12 (9.02%)

This chart shows the closing price for TMBR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Timber Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMBR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMBR

Analyst Price Target is $50.00
▲ +3,348.28% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Timber Pharmaceuticals in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 3,348.28% upside from the last price of $1.45.

This chart shows the closing price for TMBR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Timber Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/26/2022HC WainwrightLower TargetBuy$75.00 ➝ $50.00Low
8/29/2022HC WainwrightLower TargetBuy$75.00 ➝ $50.00Low
5/2/2022HC WainwrightLower Target$100.00 ➝ $75.00Low
3/31/2022HC WainwrightInitiated CoverageBuy$100.00High
(Data available from 11/30/2017 forward)

News Sentiment Rating

1.35 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/4/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/3/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2022

Current Sentiment

  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Timber Pharmaceuticals logo
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Read More

Today's Range

Now: $1.45
Low: $1.33
High: $1.53

50 Day Range

MA: $4.91
Low: $1.33
High: $76.50

52 Week Range

Now: $1.45
Low: $1.32
High: $24.95

Volume

266,288 shs

Average Volume

116,098 shs

Market Capitalization

$4.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Timber Pharmaceuticals?

The following sell-side analysts have issued research reports on Timber Pharmaceuticals in the last twelve months: HC Wainwright.
View the latest analyst ratings for TMBR.

What is the current price target for Timber Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Timber Pharmaceuticals in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 3,348.3%. HC Wainwright has the highest price target set, predicting TMBR will reach $50.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $50.00 for Timber Pharmaceuticals in the next year.
View the latest price targets for TMBR.

What is the current consensus analyst rating for Timber Pharmaceuticals?

Timber Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TMBR will outperform the market and that investors should add to their positions of Timber Pharmaceuticals.
View the latest ratings for TMBR.

What other companies compete with Timber Pharmaceuticals?

How do I contact Timber Pharmaceuticals' investor relations team?

Timber Pharmaceuticals' physical mailing address is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. The company's listed phone number is (914) 205-3481 and its investor relations email address is [email protected] The official website for Timber Pharmaceuticals is www.timberpharma.com. Learn More about contacing Timber Pharmaceuticals investor relations.